A Phase II Study of G3139 (Genasense) in Patients With Merkel Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Oblimersen (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Dec 2012 Actual end date Jan 2007 added as reported by ClinicalTrials.gov.
- 16 May 2007 Status changed from in progress to completed.